Rechercher

The IVORY Study

Maïa Klzn
15 sept. 2024
1 min de lecture

The IVORY study, conducted with the involvement of Ziad Mallat from Inserm, explored the therapeutic potential of low-dose interleukin-2 to reduce arterial inflammation in patients with acute coronary syndrome. The study demonstrated a 7.7% reduction in arterial inflammation, along with a favorable safety profile, and indicated a potential reduction in major adverse cardiovascular events. The results were presented at the ESC Congress 2024 in London.

Posts récents

Voir tout

ILTOO Pharma welcomes the publication of MIROCALS Phase IIb Trial Results in The Lancet, demonstrating Safety and Efficacy of Low-Dose IL-2 in ALS

Paris, France – May 10, 2025 – ILTOO Pharma is pleased to welcome the publication in The Lancet of the results from the MIROCALS phase IIb clinical trial ( Access the MIROCALS Trial article in The

Breakthrough from the University of Trieste Enhances Gene Therapy for Cardiovascular Diseases

The research group led by Serena Zacchigna at the University of Trieste has found a new way of improving gene therapy for cardiovascular diseases by enhancing the efficiency of gene transfer to cardia

“The Promise of Interleukin-2 Therapy” 2024: A Landmark Event in Immunotherapy Research

The 2024 edition of "The Promise of Interleukin-2 Therapy" chaired by David Klatzmann (TiilT project coordinator), concluded successfully in Paris after four days of engaging scientific exchange, he

Commentaires